A recent study indicated that treatment with the glutamine transport inhibitor V‐9302 could reduce percentages of CD4+FoxP3+CD25+CD127low Tregs in human tumor tissues.[35] Glutamine metabolism has also been reported to be critical for the recruitment and functional activity of MDSCs.[36] Glutamine antagonism has successfully resulted in reduced MDSC infiltration into the TME.[10, 36] We found that JHU083 inhibited M‐MDSCs in our tumor model. This evidence concerns the gene CD4 and neoplasm.